Testosterone propionate
Testosterone propionate is a short-acting injectable testosterone ester used as androgen replacement therapy in male hypogonadism.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
After injection the ester is hydrolysed to release testosterone, which acts on androgen receptors to support development and maintenance of male secondary sexual characteristics and related metabolic effects.
Prescribing in practice
- It is contraindicated in known or suspected prostate or male breast cancer; assess prostate health before starting, as testosterone can stimulate growth of existing prostate cancer.
- Being a short-acting ester, it requires frequent injections compared with longer-acting depot testosterone preparations.
- Androgen therapy can cause polycythaemia, fluid retention, mood changes and worsening of sleep apnoea, and is inappropriate in pregnancy.
Monitoring
Monitor haematocrit/haemoglobin, prostate-specific antigen and prostate status, lipids and serum testosterone to guide dosing.
Counselling the patient
- Regular blood tests and prostate checks are needed during treatment.
- Report difficulty passing urine, headaches, or unusual mood changes.
- This treatment is not for use during pregnancy and women should avoid skin contact with injection sites.
Evidence & guidelines
Testosterone replacement is an established treatment for confirmed male hypogonadism, with monitoring of haematocrit and prostate-specific antigen reflecting standard endocrine practice.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Cervical Cerclage Criteria (Short Cervix / Preterm Risk) · Preterm Labour
- Brief Pain Inventory — Short Form (BPI-SF) · Pain
- Montreal Cognitive — Short Screening for Substance Misuse · Substance Misuse Screening
- Short Michigan Alcoholism Screening Test (SMAST) · Alcohol Use
- Short Michigan Alcoholism Screening Test — Geriatric Version (SMAST-G) · Alcohol Use
- ICIQ-UI Short Form (Urinary Incontinence) · Incontinence
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016